Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 134.09 Million SEK | -13.22% |
| 2022 | 154.52 Million SEK | 356.12% |
| 2021 | 33.87 Million SEK | 455.56% |
| 2020 | 6.09 Million SEK | 81.27% |
| 2019 | 3.36 Million SEK | 0.18% |
| 2018 | 3.35 Million SEK | -2.44% |
| 2017 | 3.44 Million SEK | 33.46% |
| 2016 | 2.57 Million SEK | -52.54% |
| 2015 | 5.43 Million SEK | 15.22% |
| 2014 | 4.71 Million SEK | 173.07% |
| 2013 | 1.72 Million SEK | -34.05% |
| 2012 | 2.61 Million SEK | 104.24% |
| 2011 | 1.28 Million SEK | -71.17% |
| 2010 | 4.44 Million SEK | 49.08% |
| 2009 | 2.98 Million SEK | 2777.99% |
| 2008 | 103.67 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 34.33 Million SEK | -38.67% |
| 2024 Q3 | 48.66 Million SEK | 41.74% |
| 2024 Q1 | 55.98 Million SEK | 11.05% |
| 2023 Q1 | 24.19 Million SEK | -21.36% |
| 2023 Q3 | 22.83 Million SEK | -37.69% |
| 2023 FY | 134.09 Million SEK | -13.22% |
| 2023 Q4 | 50.41 Million SEK | 120.74% |
| 2023 Q2 | 36.65 Million SEK | 51.49% |
| 2022 Q2 | 26.39 Million SEK | -12.83% |
| 2022 Q1 | 30.28 Million SEK | 96.65% |
| 2022 FY | 154.52 Million SEK | 356.12% |
| 2022 Q4 | 30.76 Million SEK | -54.14% |
| 2022 Q3 | 67.08 Million SEK | 154.14% |
| 2021 Q2 | 4.53 Million SEK | -49.6% |
| 2021 Q1 | 8.99 Million SEK | 135.06% |
| 2021 FY | 33.87 Million SEK | 455.56% |
| 2021 Q3 | 4.94 Million SEK | 9.08% |
| 2021 Q4 | 15.39 Million SEK | 211.26% |
| 2020 FY | 6.09 Million SEK | 81.27% |
| 2020 Q1 | 885 Thousand SEK | -26.43% |
| 2020 Q2 | 623 Thousand SEK | -29.6% |
| 2020 Q3 | 762 Thousand SEK | 22.31% |
| 2020 Q4 | 3.82 Million SEK | 402.36% |
| 2019 Q4 | 1.2 Million SEK | 84.51% |
| 2019 Q3 | 652 Thousand SEK | 10.14% |
| 2019 Q2 | 592 Thousand SEK | -35.44% |
| 2019 Q1 | 917 Thousand SEK | -33.84% |
| 2019 FY | 3.36 Million SEK | 0.18% |
| 2018 FY | 3.35 Million SEK | -2.44% |
| 2018 Q1 | 588 Thousand SEK | -41.95% |
| 2018 Q4 | 1.38 Million SEK | 186.36% |
| 2018 Q3 | 484 Thousand SEK | -46.22% |
| 2018 Q2 | 900 Thousand SEK | 53.06% |
| 2017 Q3 | 678 Thousand SEK | -2.16% |
| 2017 Q4 | 1.01 Million SEK | 49.41% |
| 2017 FY | 3.44 Million SEK | 33.46% |
| 2017 Q1 | 1.05 Million SEK | 11.13% |
| 2017 Q2 | 693 Thousand SEK | -34.5% |
| 2016 Q1 | 542 Thousand SEK | 2.46% |
| 2016 FY | 2.57 Million SEK | -52.54% |
| 2016 Q3 | 543 Thousand SEK | 0.18% |
| 2016 Q4 | 952 Thousand SEK | 75.32% |
| 2016 Q2 | 542 Thousand SEK | 0.0% |
| 2015 FY | 5.43 Million SEK | 15.22% |
| 2015 Q1 | 3.84 Million SEK | 18.19% |
| 2015 Q3 | 529 Thousand SEK | 0.0% |
| 2015 Q2 | 529 Thousand SEK | -86.25% |
| 2015 Q4 | 529 Thousand SEK | 0.0% |
| 2014 Q3 | - SEK | -100.0% |
| 2014 Q4 | 3.25 Million SEK | 0.0% |
| 2014 Q1 | 1.61 Million SEK | 189.26% |
| 2014 Q2 | 349 Thousand SEK | -78.35% |
| 2014 FY | 4.71 Million SEK | 173.07% |
| 2013 Q3 | 557.28 Thousand SEK | 64.77% |
| 2013 Q2 | 338.21 Thousand SEK | -0.0% |
| 2013 Q4 | 557.28 Thousand SEK | 0.0% |
| 2013 Q1 | 338.21 Thousand SEK | -63.44% |
| 2013 FY | 1.72 Million SEK | -34.05% |
| 2012 Q4 | 925.07 Thousand SEK | 0.0% |
| 2012 FY | 2.61 Million SEK | 104.24% |
| 2011 FY | 1.28 Million SEK | -71.17% |
| 2010 FY | 4.44 Million SEK | 49.08% |
| 2009 FY | 2.98 Million SEK | 2777.99% |
| 2008 FY | 103.67 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -130.771% |
| Ziccum AB (publ) | 3.74 Million SEK | -3478.703% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 78.231% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -165.612% |
| Mendus AB (publ) | 28.48 Million SEK | -370.72% |
| Genovis AB (publ.) | 158.23 Million SEK | 15.255% |
| Intervacc AB (publ) | 8.01 Million SEK | -1573.038% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -2965.706% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 21.325% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -205.481% |
| Aptahem AB (publ) | 2.63 Million SEK | -4997.375% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -12855.942% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -174048.052% |
| Fluicell AB (publ) | 3.33 Million SEK | -3917.196% |
| Saniona AB (publ) | 16.84 Million SEK | -696.283% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -717.297% |
| Biovica International AB (publ) | 7.29 Million SEK | -1739.424% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -11046.633% |
| AcouSort AB (publ) | 10.55 Million SEK | -1170.913% |
| Xintela AB (publ) | 78 Thousand SEK | -171815.385% |
| Abliva AB (publ) | 137 Thousand SEK | -97778.832% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -132.802% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -6558.093% |
| OncoZenge AB (publ) | 3000.00 SEK | -4469700.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -86412.258% |
| CombiGene AB (publ) | 5.54 Million SEK | -2318.672% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 88.889% |
| Camurus AB (publ) | 1.71 Billion SEK | 92.19% |
| Corline Biomedical AB | 25.03 Million SEK | -435.733% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -2261.641% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -18498.336% |
| I-Tech AB | 120.86 Million SEK | -10.949% |
| Cyxone AB (publ) | 5.14 Million SEK | -2504.779% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -1802.043% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -1157.363% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -1094.063% |
| Nanologica AB (publ) | 1.44 Million SEK | -9192.723% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -252907.547% |
| BioInvent International AB (publ) | 71.46 Million SEK | -87.646% |
| Alzinova AB (publ) | 270 Thousand SEK | -49564.444% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -280.733% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -9065.562% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -4651.736% |
| Simris Alg AB (publ) | 4.35 Million SEK | -2979.789% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -103049.231% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 43.83% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -582917.391% |